This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Nuplazid

Acadia Pharmaceuticals, Inc.

Drug Names(s): ACP-103, pimavanserin

Description: Pimavanserin is a small molecule drug candidate and a potent and selective serotonin 5-HT2A inverse agonist, a compound that blocks the activity of this key target that plays an important role in the treatment of neuropsychiatric disorders.

Deal Structure: Acadia and Biovail (Valeant)
In May 2009, Acadia announced that it established a collaboration with Biovail Laboratories to co-develop and commercialize pimavanserin in the United States and Canada. The collaboration provides for the co-development and commercialization of pimavanserin for multiple neurological and psychiatric indications, including Parkinson's disease psychosis (PDP) and Alzheimer's disease psychosis (ADP). Biovail will lead other development, manufacturing, and commercialization efforts for pimavanserin, including activities directed at ADP and other potential indications.

Under the terms of the collaboration, Acadia is entitled to receive aggregate payments, excluding royalties, of up to $395 million. These include an upfront cash payment of $30 million, up to $160 million in potential milestone payments associated with the successful completion of clinical trials, regulatory submissions and approvals of pimavanserin for PDP and ADP, up to $45...See full deal structure in Biomedtracker


Nuplazid News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug